Deloris
15 April 2022 16:06 | Schnessnitz
Also provided for use in combination with a lyophilized formulation of Compound 1 provided herein are native, naturally occurring, and recombinant proteins.
Recombinant and mutated forms of GM-CSF can be prepared as described in U.S. Second active agents can be large molecules (e.g., proteins) or small molecules (e.g., synthetic inorganic, organometallic, or organic molecules). Second active agents that are small molecules can also be used to alleviate adverse effects associated with the administration of a lyophilized formulation of Compound 1 provided herein. A lyophilized formulation of Compound 1 provided herein can also be combined or used in combination with other therapeutic agents useful in the treatment and/or prevention of MDS described herein. In a particular embodiment, Compound 1 can be administered in an amount of about 10 mg/day to patients with MDS.
In a particular embodiment, Compound 1 provided herein can be administered in an amount of about 3 mg/day to patients with MDS.